Replies to post #242055 on Biotech Values

[DewDiligence]

AMRN -42% on weak 1Q22 Vascepa sales:

https://www.globenewswire.com/news-release/2022/05/04/2435525/18362/en/Amarin-Reports-First-Quarter-2022-Financial-Results-and-Provides-Business-Update.html

Net product revenue for the first quarter ended March 31, 2022 was $94.0 million compared to $141.4 million in the corresponding period of 2021, a decrease of 34%. Approximately half of this decrease was driven by a decline in volume. The balance of the decrease was a result of selling initiatives focused on certain customers to maximize prescription fulfillment. As a reminder, during the three months ended March 31, 2022 there were three generic competitors in the market as compared to one generic competitor in the market during the three months ended March 31, 2021.